28.34M
Market cap
Current P/E
Forward P/E

About

Health care
Sector
Biotechnology
Industry

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.

Similar securities

Based on sector and market capitalization

Report issue